nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—AVPR2—nephron—focal segmental glomerulosclerosis	0.305	0.667	CbGeAlD
Tolvaptan—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.214	0.625	CbGbCtD
Tolvaptan—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.128	0.375	CbGbCtD
Tolvaptan—AVPR2—nephron tubule—focal segmental glomerulosclerosis	0.0659	0.144	CbGeAlD
Tolvaptan—AVPR2—kidney—focal segmental glomerulosclerosis	0.0579	0.127	CbGeAlD
Tolvaptan—CYP3A4—kidney—focal segmental glomerulosclerosis	0.00882	0.0193	CbGeAlD
Tolvaptan—AVPR2—Arf6 trafficking events—AGTR1—focal segmental glomerulosclerosis	0.00735	0.0521	CbGpPWpGaD
Tolvaptan—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.00711	0.0155	CbGeAlD
Tolvaptan—AVPR1A—Peptide GPCRs—AGTR2—focal segmental glomerulosclerosis	0.00669	0.0475	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide GPCRs—AGTR2—focal segmental glomerulosclerosis	0.00665	0.0471	CbGpPWpGaD
Tolvaptan—ABCB1—kidney—focal segmental glomerulosclerosis	0.00624	0.0136	CbGeAlD
Tolvaptan—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.00608	0.0133	CbGeAlD
Tolvaptan—AVPR1A—Peptide GPCRs—AGTR1—focal segmental glomerulosclerosis	0.00515	0.0365	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide GPCRs—AGTR1—focal segmental glomerulosclerosis	0.00511	0.0362	CbGpPWpGaD
Tolvaptan—Vismodegib—ALB—focal segmental glomerulosclerosis	0.00399	1	CrCbGaD
Tolvaptan—AVPR1A—G alpha (q) signalling events—TRPC6—focal segmental glomerulosclerosis	0.00321	0.0227	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.00315	0.0223	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—AGTR2—focal segmental glomerulosclerosis	0.00313	0.0222	CbGpPWpGaD
Tolvaptan—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.00309	0.0559	CcSEcCtD
Tolvaptan—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00295	0.0533	CcSEcCtD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—TRPC6—focal segmental glomerulosclerosis	0.00287	0.0203	CbGpPWpGaD
Tolvaptan—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00279	0.0504	CcSEcCtD
Tolvaptan—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00269	0.0486	CcSEcCtD
Tolvaptan—AVPR1A—G alpha (q) signalling events—GNAQ—focal segmental glomerulosclerosis	0.00268	0.019	CbGpPWpGaD
Tolvaptan—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.00248	0.0447	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00246	0.0175	CbGpPWpGaD
Tolvaptan—AVPR1A—G alpha (q) signalling events—AGTR1—focal segmental glomerulosclerosis	0.00245	0.0174	CbGpPWpGaD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—AGTR2—focal segmental glomerulosclerosis	0.00245	0.0174	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—AGTR1—focal segmental glomerulosclerosis	0.00242	0.0172	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—AGTR1—focal segmental glomerulosclerosis	0.0024	0.017	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—GNAQ—focal segmental glomerulosclerosis	0.0024	0.017	CbGpPWpGaD
Tolvaptan—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.00226	0.0409	CcSEcCtD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—focal segmental glomerulosclerosis	0.00219	0.0156	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.00211	0.015	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—AGTR2—focal segmental glomerulosclerosis	0.0021	0.0149	CbGpPWpGaD
Tolvaptan—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00209	0.0377	CcSEcCtD
Tolvaptan—AVPR1A—G alpha (q) signalling events—EDN1—focal segmental glomerulosclerosis	0.00208	0.0147	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.00205	0.0146	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—EDN1—focal segmental glomerulosclerosis	0.00204	0.0144	CbGpPWpGaD
Tolvaptan—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00204	0.0368	CcSEcCtD
Tolvaptan—AVPR1A—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.0019	0.0134	CbGpPWpGaD
Tolvaptan—AVPR2—GPCRs, Class A Rhodopsin-like—AGTR1—focal segmental glomerulosclerosis	0.00188	0.0133	CbGpPWpGaD
Tolvaptan—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00186	0.0336	CcSEcCtD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—focal segmental glomerulosclerosis	0.00186	0.0132	CbGpPWpGaD
Tolvaptan—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0018	0.0325	CcSEcCtD
Tolvaptan—AVPR1A—G alpha (q) signalling events—AGT—focal segmental glomerulosclerosis	0.00173	0.0122	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.0017	0.0121	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—AGT—focal segmental glomerulosclerosis	0.00169	0.012	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00162	0.0115	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—AGTR1—focal segmental glomerulosclerosis	0.00161	0.0114	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.00161	0.0114	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—AGTR2—focal segmental glomerulosclerosis	0.0016	0.0113	CbGpPWpGaD
Tolvaptan—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00159	0.0287	CcSEcCtD
Tolvaptan—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00155	0.028	CcSEcCtD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—focal segmental glomerulosclerosis	0.00154	0.0109	CbGpPWpGaD
Tolvaptan—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00151	0.0272	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.00138	0.00976	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—EDN1—focal segmental glomerulosclerosis	0.00137	0.00969	CbGpPWpGaD
Tolvaptan—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00136	0.0245	CcSEcCtD
Tolvaptan—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.0244	CcSEcCtD
Tolvaptan—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00135	0.0244	CcSEcCtD
Tolvaptan—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00125	0.0225	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.00124	0.00881	CbGpPWpGaD
Tolvaptan—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00124	0.0224	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.00124	0.00877	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—AGTR1—focal segmental glomerulosclerosis	0.00123	0.00871	CbGpPWpGaD
Tolvaptan—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.0216	CcSEcCtD
Tolvaptan—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00117	0.0212	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.00114	0.0081	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—AGT—focal segmental glomerulosclerosis	0.00113	0.00804	CbGpPWpGaD
Tolvaptan—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00111	0.0201	CcSEcCtD
Tolvaptan—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.0195	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.00105	0.00743	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	0.00104	0.00741	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—EDN1—focal segmental glomerulosclerosis	0.00104	0.00738	CbGpPWpGaD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.0183	CcSEcCtD
Tolvaptan—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.0182	CcSEcCtD
Tolvaptan—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000997	0.018	CcSEcCtD
Tolvaptan—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000977	0.0177	CcSEcCtD
Tolvaptan—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000958	0.0173	CcSEcCtD
Tolvaptan—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000949	0.0171	CcSEcCtD
Tolvaptan—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000931	0.0168	CcSEcCtD
Tolvaptan—ABCB1—Allograft Rejection—AGTR1—focal segmental glomerulosclerosis	0.000924	0.00655	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000914	0.00648	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000909	0.00644	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—TRPC6—focal segmental glomerulosclerosis	0.000907	0.00643	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—EDN1—focal segmental glomerulosclerosis	0.000904	0.00641	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—AGTR2—focal segmental glomerulosclerosis	0.000902	0.0064	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.00087	0.00617	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—AGT—focal segmental glomerulosclerosis	0.000864	0.00613	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000859	0.00609	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	0.000852	0.00605	CbGpPWpGaD
Tolvaptan—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000849	0.0153	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000843	0.0152	CcSEcCtD
Tolvaptan—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000835	0.0151	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.00083	0.00589	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000825	0.00585	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—TRPC6—focal segmental glomerulosclerosis	0.000824	0.00584	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—AGTR2—focal segmental glomerulosclerosis	0.000819	0.00581	CbGpPWpGaD
Tolvaptan—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000805	0.0145	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000789	0.0056	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	0.000783	0.00556	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—CD40LG—focal segmental glomerulosclerosis	0.000774	0.00549	CbGpPWpGaD
Tolvaptan—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000772	0.014	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000764	0.00542	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—GNAQ—focal segmental glomerulosclerosis	0.000759	0.00538	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.00072	0.013	CcSEcCtD
Tolvaptan—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000701	0.0127	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000699	0.00496	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000694	0.00492	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—AGTR1—focal segmental glomerulosclerosis	0.000694	0.00492	CbGpPWpGaD
Tolvaptan—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000691	0.0125	CcSEcCtD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	0.000689	0.00489	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—GNAQ—focal segmental glomerulosclerosis	0.000689	0.00488	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—NOS2—focal segmental glomerulosclerosis	0.000685	0.00486	CbGpPWpGaD
Tolvaptan—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000668	0.0121	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000667	0.00473	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	0.000662	0.00469	CbGpPWpGaD
Tolvaptan—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000646	0.0117	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.000635	0.0045	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—AGTR1—focal segmental glomerulosclerosis	0.00063	0.00447	CbGpPWpGaD
Tolvaptan—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000612	0.0111	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000592	0.0042	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—EDN1—focal segmental glomerulosclerosis	0.000588	0.00417	CbGpPWpGaD
Tolvaptan—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00058	0.0105	CcSEcCtD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—focal segmental glomerulosclerosis	0.000577	0.00409	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000538	0.00381	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—EDN1—focal segmental glomerulosclerosis	0.000534	0.00379	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	0.000513	0.00364	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000492	0.00349	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.00049	0.00348	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	0.000488	0.00346	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000487	0.00346	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	0.000487	0.00345	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	0.000484	0.00343	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000447	0.00317	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	0.000443	0.00314	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.00041	0.00291	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	0.000407	0.00289	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000375	0.00266	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	0.000372	0.00264	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	0.000349	0.00247	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000318	0.00225	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—TGFB1—focal segmental glomerulosclerosis	0.000316	0.00224	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	0.000316	0.00224	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000308	0.00219	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	0.000306	0.00217	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.000292	0.00207	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	0.00029	0.00206	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000264	0.00187	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	0.000262	0.00186	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000244	0.00173	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	0.000242	0.00172	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	0.000237	0.00168	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000203	0.00144	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	0.000201	0.00143	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	0.000156	0.0011	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000155	0.0011	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	0.000154	0.00109	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000128	0.000908	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	0.000127	0.000901	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	0.000114	0.00081	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	0.000101	0.000713	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	9.77e-05	0.000693	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.27e-05	0.000657	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	7.04e-05	0.000499	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	6.97e-05	0.000495	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	6.2e-05	0.00044	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	5.97e-05	0.000423	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.71e-05	0.000405	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	4.58e-05	0.000325	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	4.3e-05	0.000305	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	3.68e-05	0.000261	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	2.82e-05	0.0002	CbGpPWpGaD
